GlassScriptPhysician profile
Paul K Wein
NPI 1669470548
$1,764.16
in general payments reported to CMS, 2019-2025
21 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2021: $16.67 · 2022: $243 · 2023: $626 · 2024: $231 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.39 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $183.08 | 2023 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $152.87 | 2023-2025 | |
| Medtronic Vascular, INC. | $152.40 | 2019 | |
| Pfizer INC. | $128.30 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $122.97 | 2022-2023 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $114.35 | 2022-2025 | Jynarque, Voyxact |
| Janssen Pharmaceuticals, INC | $103.99 | 2022-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $97.09 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $93.82 | 2025 | |
| Akebia Therapeutics INC | $50.42 | 2025 | Vafseo |
| Lilly USA, LLC | $49.98 | 2023 | Mounjaro |
| Vifor Pharma, INC. | $45.20 | 2019-2022 | |
| Csl Behring | $33.00 | 2023 | Kcentra |
| Novo Nordisk INC | $25.00 | 2023 | Rybelsus, Ozempic |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.81 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $23.18 | 2024 | Arexvy |
| Ardelyx, INC. | $22.64 | 2025 | Ibsrela |
| Baxter Healthcare | $19.68 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $19.15 | 2025 | Watchman Flx |
| Amgen INC. | $15.84 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.